DarshanTalks Podcast

Send us Fan Mail Episode Summary: "We are 100% HIPAA compliant." If this claim sits on your clinical trial site, digital health app, or pharma landing page, you may be quietly accumulating catastrophic compliance debt. In this episode of the KF Deep Dive , host Darshan Kulkarni sits down with technology and privacy attorney Brandi Bennett (Founder & Managing Partner of Bennett Tech L...

Send us Fan Mail Episode Overview: In this episode of KLF Deep Dive , host Darshan Kulkarni sits down with Deborah Williams, Founder of Health Policy Insights, LLC, to explore over three decades of healthcare policy evolution. Deborah brings a wealth of experience as a policy researcher, former congressional staffer, and former lobbyist to break down the complexities surrounding the 340B Drug Pric...

Send us Fan Mail The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the Darshan Live podcast, host Darshan Kulkarni sits down with healthcare regulatory attorney Kate Woods and former public defender turned sauna master Mackenzie Boling to pull back the curtain on...

Send us Fan Mail When podcast hosts and biohacking influencers promote "The Wolverine Stack"—coupling BPC-157 and TB-500 for rapid tissue and gut repair—it generates millions of dollars in consumer demand. But how does viral influencer marketing translate into real-world legal and regulatory risk? In this episode of Darshan Talks / KLF Deep Dive , host Darshan Kulkarni breaks down the my...

Send us Fan Mail What is happening inside the FDA, and how are regulatory shifts impacting pharmaceutical, medical device, and food companies? In this episode of the  KLF Deep Dive , host Darshan Kulkarni sits down with veteran Food and Drug lawyer Alan Minsk (Partner and Chair of the Food & Drug Practice at Arnall Golden Gregory LLP) to discuss the evolving enforcement climate, agency turnove...

Send us Fan Mail Thinking about launching a health tech startup, digital health app, or wearable device? Moving fast and breaking things might work in software, but in healthcare, breaking things means breaking people. In this episode of the KLF Deep Dive , host Darshan Kulkarni connects with Emily Hu Shapiro—a Silicon Valley native, chemical/biomedical engineer, former Google clinical research le...

Send us Fan Mail The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the KLF Deep Dive , host Darshan Kulkarni sits down with healthcare regulatory attorney Kate Woods and former public defender turned sauna master McKenzie Bowling to pull back the curtain on the r...

Send us Fan Mail Thinking about launching a health product, dietary supplement, or digital health solution in the Australian market? You might want to hit pause before assuming your U.S. or European regulatory strategy will translate. In this episode of the  KLF Deep Dive , host Daran Carney connects with Isabelle Petour, Principal of Launchpad Regulatory, a boutique regulatory affairs firm based...

Send us Fan Mail What happens when an artificial intelligence chatbot moves past answering basic questions and starts actively pretending to be a licensed psychiatrist? In this episode of the KLF Deep Dive , host Daran Carney welcomes premier healthcare regulatory and privacy attorney Elizabeth Litton, Chief Privacy and HIPAA Compliance Officer at Fox Rothschild. Together, they break down the expl...

Send us Fan Mail Think clinical trial compliance is just a part-time job or a paperwork exercise that can be passed off to a medical assistant? Think again. In this episode of the KLF Deep Dive , host Daran Carney sits down with Tom Sepka, CEO of HCI Healthcare Consultants and veteran Chief Pharmacy Officer, to shatter the myth that research pharmacy oversight is optional. Together, they break dow...

Send us Fan Mail How a "Failed" 4-Minute Molecule Created a Trillion-Dollar Cultural Eclipse Imagine pitching a drug to a room of venture capitalists that is biologically perfect—except for one tiny flaw: the human body completely destroys it in four minutes flat. That is the exact garbage hand Danish pharma giant Novo Nordisk was dealt in the 1990s. Today, that exact same molecule is Oz...

Send us Fan Mail What happens when an artificial intelligence chatbot generates a fake medical license number and starts giving psychiatric advice? In this episode of the KF Deep Dive , host Darshan welcomes healthcare regulatory expert and Fox Rothschild Chief Privacy Officer, Elizabeth Litten, to untangle a wild new frontier in legal tech. We break down the historic lawsuit filed by Pennsylvania...

Send us Fan Mail  NOT LEGAL ADVICE  For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370 , the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed. In this episode of KLF Deep Dive , attorney-...

Send us Fan Mail Is your career protected from your company’s mistakes? For decades, a Federal Consent Decree was a corporate headache. Today, it’s a personal professional death sentence. In this episode, Darshan Kulkarni breaks down the seismic shift in federal enforcement: why agencies are now naming CEOs, CMOs, and Heads of Clinical operations by name in injunctions. We explore the "Delega...

Send us Fan Mail  In this episode of the KLF Deep Dive , Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil liability, the reality in federal court is starkly different. Darshan examines the constitu...

Send us Fan Mail  What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal li...

Send us Fan Mail  In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site...

Send us Fan Mail  In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional...

Send us Fan Mail Stop playing compliance theater. In this episode, Darshan Kulkarni pulls back the curtain on a dangerous trend in the life sciences: the over-reliance on contract sales forces without the legal control to back them up. Many companies believe they’ve "solved" the incentive pay problem, only to realize the OIG hasn't changed its mind since 1998. We break down why the...

Send us Fan Mail  Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into the murky waters of AI-driven sponsor protocols. We explore how AI is being used to mask—and unmask—data falsification, and what life science sponsors must do to ensure compliance before the regulators knock. If you’re using AI to "make life ea...

Send us Fan Mail "The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments. We dive deep into the three pillars of risk tha...

Send us Fan Mail In this episode of DarshanTalks , host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling your symptoms" to "Chatting with your symptoms." It’s 10:47 PM—you have chest tightness and a chatbot is your only companion. But is the algorithm reassuring you, or is it gaslighting a medical emergency? We go beyond the hype to exa...

Send us Fan Mail  On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizin...

Send us Fan Mail The DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Personal Data" to countries of concern—specifically China—is no longer just a compliance hurdle; it’s a potential federal violation. In this episode, Darshan Kulkarni breaks down the six categories of data you must protect immediately, from genomic...

Send us Fan Mail Is your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching closely. We break down the three massive risks facing life science companies and healthcare...